Custirsen

DGAP-News: Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals' LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids

Retrieved on: 
Tuesday, January 19, 2021
Branches of biology, Biology, ANGPTL4, Molecular biology, RNA, Molecules, Sense, Lipid metabolism, Triglyceride, Oligonucleotide, Custirsen, Secarna's proprietary drug discovery platform, LNAplusTM, Secarna Pharmaceuticals GmbH & Co. KG, Lipigon Pharmaceuticals

Lipisense, an antisense oligonucleotide (ASO) which has been developed with Secarna's proprietary LNAplusTM platform, is a first-in-class treatment with a novel mechanism of action central for the regulation of plasma triglycerides and other plasma lipids.

Key Points: 
  • Lipisense, an antisense oligonucleotide (ASO) which has been developed with Secarna's proprietary LNAplusTM platform, is a first-in-class treatment with a novel mechanism of action central for the regulation of plasma triglycerides and other plasma lipids.
  • The drug candidate hinders the cellular production of ANGPTL4, a protein that has a direct role in lipid metabolism by blocking the clearance of triglycerides.
  • The LNAplusTM ASO-based drug candidate has shown strong efficacy in experimental disease models and a good safety profile in preliminary safety studies.
  • About Secarna's proprietary drug discovery platform, LNAplusTM
    For discovering, testing and selecting antisense oligonucleotides (ASOs) for pre-clinical and clinical development, Secarna employs its proprietary, customized LNAplusTM drug discovery platform.

Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer

Retrieved on: 
Thursday, August 27, 2020
Bioavailability, Medicinal chemistry, Life sciences, Medicine, Clinical medicine, Palifermin, Custirsen

DRIIV was instrumental in demonstrating the good safety profile and activity of AsiDNA via the IV route.

Key Points: 
  • DRIIV was instrumental in demonstrating the good safety profile and activity of AsiDNA via the IV route.
  • DRIIV demonstrated AsiDNAs favorable safety profile and validated its activity in patients tumor cells through a robust activation of its biological targets.
  • Most importantly, the optimal active dose of 600 mg was determined and is currently being utilized in our ongoing combination studies.
  • The publication titled A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours is available on the British Journal of Cancer website .

Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

Retrieved on: 
Friday, May 29, 2020
Dose, Toxicology, Health, Medicine, Clinical medicine, Prostate cancer, Prostvac, Custirsen

The on-going dose escalation Phase 1 study has enrolled 44 patients with progressive, metastatic castration-resistant prostate cancer in 11 cohorts.

Key Points: 
  • The on-going dose escalation Phase 1 study has enrolled 44 patients with progressive, metastatic castration-resistant prostate cancer in 11 cohorts.
  • Management to host webcast and conference call to review the interim Phase 1 data and provide a pipeline update today at 4 p.m.
  • The presentation highlights interim results in 44 patients across 11 dosing cohorts treated with HPN424 from the ongoing dose escalation portion of a Phase 1 clinical trial.
  • The initial ongoing phase of the trial is dose escalation, with the goal of determining a recommended dose for the expansion phase.